A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches

Abstract Background Glioblastoma multiforme (GBM) is a lethal brain tumor. With the current gold standard chemotherapy treatment, temozolomide (TMZ), many patients do not survive beyond one year. While the urgency of researching novel treatments is understandable, the prohibitively high costs and th...

Full description

Saved in:
Bibliographic Details
Main Authors: Meijun Liu, Yuying Wang, Xiaoli Chen, Yu Zeng, Wenqiong Huang, Jiawen Yang, Hong Dai, Lixin Cheng, Claudio Mauro, Kenneth Chat Pan Cheung
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Clinical Epigenetics
Subjects:
Online Access:https://doi.org/10.1186/s13148-025-01900-5
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850113025539833856
author Meijun Liu
Yuying Wang
Xiaoli Chen
Yu Zeng
Wenqiong Huang
Jiawen Yang
Hong Dai
Lixin Cheng
Claudio Mauro
Kenneth Chat Pan Cheung
author_facet Meijun Liu
Yuying Wang
Xiaoli Chen
Yu Zeng
Wenqiong Huang
Jiawen Yang
Hong Dai
Lixin Cheng
Claudio Mauro
Kenneth Chat Pan Cheung
author_sort Meijun Liu
collection DOAJ
description Abstract Background Glioblastoma multiforme (GBM) is a lethal brain tumor. With the current gold standard chemotherapy treatment, temozolomide (TMZ), many patients do not survive beyond one year. While the urgency of researching novel treatments is understandable, the prohibitively high costs and the prolonged duration of research and clinical trials significantly delay the availability of medical advancements to the general public. This highlights the urgent need for adjuvant therapies to enhance treatment effectiveness. Main body: Recent research has suggested the potential of repurposing FDA-approved drugs such as temozolomide (TMZ), disulfiram (DSF), and aspirin for the treatment of glioblastoma, with encouraging evidence particularly for DSF and aspirin. Additionally, compounds like histone deacetylase inhibitors (e.g., vorinostat) are being investigated for their impact on non-coding RNA (ncRNA) modulation, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Combining traditional therapies with ncRNA modulation has shown potential in enhancing therapeutic efficacy and targeting specificity. NcRNAs play a crucial role in regulating gene expression and have been implicated in tumor growth, invasion, and treatment resistance. Recent discoveries, such as cuproptosis, offer new insights into tumor cell death mechanisms. Conclusion This review focuses on how these molecular insights can serve as novel therapeutic targets and how drug adjuvant therapy may improve GBM treatment strategies. It focuses on how the integration of ncRNA modulation with conventional therapies and the combination strategy of enhancing efficacy of drugs can enhance treatment efficacy and pave the way for innovative approaches in managing GBM. In short, we will explore how non-coding RNAs (ncRNAs) might serve as promising targets and how repurposing TMZ, DSF, and aspirin could help enhance the efficacy of GBM treatment. Graphical abstract
format Article
id doaj-art-a1d1ec596f534772b3eb1cfaadb34820
institution OA Journals
issn 1868-7083
language English
publishDate 2025-06-01
publisher BMC
record_format Article
series Clinical Epigenetics
spelling doaj-art-a1d1ec596f534772b3eb1cfaadb348202025-08-20T02:37:14ZengBMCClinical Epigenetics1868-70832025-06-0117111710.1186/s13148-025-01900-5A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approachesMeijun Liu0Yuying Wang1Xiaoli Chen2Yu Zeng3Wenqiong Huang4Jiawen Yang5Hong Dai6Lixin Cheng7Claudio Mauro8Kenneth Chat Pan Cheung9Phenome Research Center, Hong Kong Baptist UniversityPhenome Research Center, Hong Kong Baptist UniversityPhenome Research Center, Hong Kong Baptist UniversityPhenome Research Center, Hong Kong Baptist UniversityPhenome Research Center, Hong Kong Baptist UniversitySchool of Life Science, Southern University of Science and TechnologyDepartment of Chemistry, Hong Kong University of Science and TechnologyHealth Data Science Center, Shenzhen People’s Hospital, First Affiliated Hospital of Southern, University of Science and TechnologyCollege of Medicine and Health, University of Birmingham, Queen Elizabeth HospitalPhenome Research Center, Hong Kong Baptist UniversityAbstract Background Glioblastoma multiforme (GBM) is a lethal brain tumor. With the current gold standard chemotherapy treatment, temozolomide (TMZ), many patients do not survive beyond one year. While the urgency of researching novel treatments is understandable, the prohibitively high costs and the prolonged duration of research and clinical trials significantly delay the availability of medical advancements to the general public. This highlights the urgent need for adjuvant therapies to enhance treatment effectiveness. Main body: Recent research has suggested the potential of repurposing FDA-approved drugs such as temozolomide (TMZ), disulfiram (DSF), and aspirin for the treatment of glioblastoma, with encouraging evidence particularly for DSF and aspirin. Additionally, compounds like histone deacetylase inhibitors (e.g., vorinostat) are being investigated for their impact on non-coding RNA (ncRNA) modulation, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Combining traditional therapies with ncRNA modulation has shown potential in enhancing therapeutic efficacy and targeting specificity. NcRNAs play a crucial role in regulating gene expression and have been implicated in tumor growth, invasion, and treatment resistance. Recent discoveries, such as cuproptosis, offer new insights into tumor cell death mechanisms. Conclusion This review focuses on how these molecular insights can serve as novel therapeutic targets and how drug adjuvant therapy may improve GBM treatment strategies. It focuses on how the integration of ncRNA modulation with conventional therapies and the combination strategy of enhancing efficacy of drugs can enhance treatment efficacy and pave the way for innovative approaches in managing GBM. In short, we will explore how non-coding RNAs (ncRNAs) might serve as promising targets and how repurposing TMZ, DSF, and aspirin could help enhance the efficacy of GBM treatment. Graphical abstracthttps://doi.org/10.1186/s13148-025-01900-5Glioblastoma multiformeTemozolomideDisulfiramCuproptosisAspirinNon-coding RNA
spellingShingle Meijun Liu
Yuying Wang
Xiaoli Chen
Yu Zeng
Wenqiong Huang
Jiawen Yang
Hong Dai
Lixin Cheng
Claudio Mauro
Kenneth Chat Pan Cheung
A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches
Clinical Epigenetics
Glioblastoma multiforme
Temozolomide
Disulfiram
Cuproptosis
Aspirin
Non-coding RNA
title A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches
title_full A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches
title_fullStr A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches
title_full_unstemmed A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches
title_short A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches
title_sort novel approach to enhance glioblastoma multiforme treatment efficacy non coding rna targeted therapy and adjuvant approaches
topic Glioblastoma multiforme
Temozolomide
Disulfiram
Cuproptosis
Aspirin
Non-coding RNA
url https://doi.org/10.1186/s13148-025-01900-5
work_keys_str_mv AT meijunliu anovelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT yuyingwang anovelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT xiaolichen anovelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT yuzeng anovelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT wenqionghuang anovelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT jiawenyang anovelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT hongdai anovelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT lixincheng anovelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT claudiomauro anovelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT kennethchatpancheung anovelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT meijunliu novelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT yuyingwang novelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT xiaolichen novelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT yuzeng novelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT wenqionghuang novelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT jiawenyang novelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT hongdai novelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT lixincheng novelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT claudiomauro novelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches
AT kennethchatpancheung novelapproachtoenhanceglioblastomamultiformetreatmentefficacynoncodingrnatargetedtherapyandadjuvantapproaches